Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Post-Vaccination Symptomatic SARS-CoV-2 Infections are Minimal and Non-Serious: An Observational Multicenter Indian Cohort Study of 28342 Healthcare Workers
29 Pages Posted: 20 Jul 2021
More...Abstract
Background: The healthcare workers (HCWs) have been on the frontline in combating the pandemic and were prioritized for vaccination when COVID-19 vaccines became available. Although vaccines effectively prevent infection in most cases, some cases of post-vaccination infections have been reported, raising concerns about vaccine efficacy. This study investigated the efficacy of COVID-19 vaccines in preventing and reducing the severity of post-vaccination infections (PVI) among HCWs.
Methods: This observational study examined 28342 vaccinated HCWs with SARS-CoV-2 (symptomatic severe acute respiratory syndrome coronavirus 2) infections during the initial five months of vaccination (January 16-June 15, 2021). They worked at 43 Apollo Group hospitals in 24 Indian cities. PVI was investigated after recombinant ChAdOx nCOV-19 (Recombinant) or the whole virion inactivated Vero cell vaccines were administered. Various parameters were evaluated such as age, sex, time to infection, type of vaccine, infections after a single and two doses, monthly and regional case distribution, clinical severity of infection, hospitalization and intensive care unit (ICU) requirement, and death.
Findings: Symptomatic PVIs occurred in a low percentage of vaccinated cohorts (5⸱07%, p<0⸱001), and these were predominantly mild and did not result in hospitalization, ICU admissions (p<0⸱0001), or death. Both vaccines provided similar protection, with PVI incidences of 5⸱11% and 4⸱58%, following ChAdOx nCOV-19 (Recombinant) and the whole virion inactivated Vero cell vaccines, respectively (p<0⸱001). Nursing and Clinical staff and cohorts>50 years significantly contracted more infections(p<0⸱001 and p=0⸱001, respectively). Two-dose vaccination has significantly lower odds of developing PVI (0.83, 95%CI – 0.72 to 0.97). Maximum infections occurred during the peak of the second COVID-19 wave from mid-April to May 2021 (p<0⸱001). No significant difference existed in the infection between sex, vaccine type, and the number of vaccine doses received (p≥0⸱05).
Interpretation: PVI occurred in a small percentage of HCWs. Vaccination protected them significantly from the infection but also severe disease.
Funding Information: None.
Declaration of Interests: None.
Ethics Approval Statement: This study was approved by an Ethical Institutional Committee (EIC), and a consent waiver was given by the EIC.
Suggested Citation: Suggested Citation